908 Devices Inc.

MASS • Medical - Specialties

$10.05

— 0.00 (0.00%)

ResultadosÚltimo reporte: 31 mar 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$370.03M

Crecimiento

-7.7%

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.12Liquidez saludable · 4.24Tendencia de crecimiento negativaRentabilidad débil

Datos financieros hasta: 31 mar 2026, 12:00 a.m. UTCÚltima actualización de earnings: 6 may 2026, 12:00 a.m. UTCÚltima actualización del perfil: 5 ago 2026, 2:36 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$10.05

Change0.00%

Shares Out36.82M

Market Cap$370.03M

Enterprise Value$258.29M

52W Range5.03 - 9.34

Beta0.53

P/E-10.31

P/S6.40

P/B2.76

P/FCF-43.94

EV/Sales4.47

Price$10.05

Change0.00%

Shares Out36.82M

Market Cap$370.03M

Enterprise Value$258.29M

52W Range5.03 - 9.34

Beta0.53

P/E-10.31

P/S6.40

P/B2.76

P/FCF-43.94

EV/Sales4.47

EV/EBITDA-9.72

EV/FCF-30.67

Earnings Yield-9.70%

FCF Yield-2.28%

Dividend Yield0.00%

Gross Margin47.68%

Oper. Margin-43.03%

Profit Margin-65.20%

Debt/Eq0.12

Current Ratio4.24

Quick Ratio3.86

Revenue 5Y-7.69%

Target$12.00

Target Upside19.40%

Target Median$12.00

Target Range12.00 - 12.00

Volume255.36K

Avg Volume271.34K

EPS Surprise-0.07

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

27/100

Atractivo del precio

Barata o cara hoy

84/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.12Liquidez saludable · 4.24Tendencia de crecimiento negativaRentabilidad débil

Analyst view

Analyst sentiment and price target

MASS

Analyst sentiment

Based on 6 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-09-05

Bajo

$12.00

Promedio

$12.00

Mediana

$12.00

Alto

$12.00

Resumen de la compañía

IPO: 12/18/2020

Industria: Medical - Specialties

P/B i: 2.76

Deuda / Patrimonio i: 0.12

Margen operativo: -43.03%

Margen neto: -65.20%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.12

Ratio corriente: 4.24

Ratio rápido: 3.86

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Spoto Mark

Transacción: 06/11/2026

COMPRA

Cambio

+6,209

Precio

$8.22

Presentación

06/12/2026

Tipo

COMPRA

Spoto Mark

Transacción: 06/11/2026

COMPRA

Cambio

+13,656

Precio

Not reported

Presentación

06/12/2026

Tipo

COMPRA

CRANDELL KEITH

Transacción: 06/11/2026

COMPRA

Cambio

+6,209

Precio

$8.22

Presentación

06/12/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Spoto Mark	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
Spoto Mark	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
CRANDELL KEITH	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
CRANDELL KEITH	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
ELOI FENEL M	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
ELOI FENEL M	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
Hunt Anthony	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
Hunt Anthony	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
HRUSOVSKY E KEVIN	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
HRUSOVSKY E KEVIN	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
Leonhart Michele M.	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
Leonhart Michele M.	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
Vann Brandi C	COMPRA	+6,209	$8.22	06/11/2026	06/12/2026
Vann Brandi C	COMPRA	+13,656	Not reported	06/11/2026	06/12/2026
Spoto Mark	VENTA	-14,083	Not reported	06/10/2026	06/12/2026
Spoto Mark	COMPRA	+14,083	Not reported	06/10/2026	06/12/2026
CRANDELL KEITH	VENTA	-14,083	Not reported	06/10/2026	06/12/2026
CRANDELL KEITH	COMPRA	+14,083	Not reported	06/10/2026	06/12/2026
ELOI FENEL M	VENTA	-14,083	Not reported	06/10/2026	06/12/2026
ELOI FENEL M	COMPRA	+14,083	Not reported	06/10/2026	06/12/2026

Sobre la compañía

908 Devices Inc.

908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company’s products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spectroscopy to identify, quantify, and track gases and vapors; ThreatID, a portable FTIR device that rapidly detects and identifies approximately 28,000 unknown gas, vapor, powder, and liquid chemical hazards; ProtectIR, a handheld FTIR device that can identify approximately 23,000 solid and liquid chemical hazards; and VipIR, a handheld 3-in-1 analyzer that integrates FTIR, Raman spectroscopy, and smart spectral processing (SSP), a proprietary algorithm, to provide a single result from just one sample. It operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of Americas. The company was incorporated in 2012 and is headquartered in Burlington, Massachusetts.

Fuente - Link

Competidores

ACRS CAPR CERS CVRX NNOX NPCE QTRX SENS SGHT SNWV

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

BlackRock Inc. Takes $16.91 Million Position in 908 Devices Inc. $MASS

BlackRock Inc. acquired a new stake in shares of 908 Devices Inc. (NASDAQ: MASS) in the quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,944,236 shares of the company's stock, valued at approximately $16,915,000. BlackRock Inc. owned approximately 5.14% of

Defense World

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium

BURLINGTON, Mass.--(BUSINESS WIRE)--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will participate in the upcoming 32nd Annual Gabelli Aerospace & Defense Symposium on September 10, 2026, in New York City.908 Devices' management is scheduled to present at 3:45 p.m. Eastern Time. The presentation is webcast and interested parties can register for th.

Business Wire

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates

908 Devices (NASDAQ: MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said the company has spent the past 18 months reshaping its operations around portable tools

Defense World

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates

908 Devices NASDAQ: MASS outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue.

MarketBeat

Is 908 Devices Inc (MASS) Overvalued After 3.3% Rally? GF Value Says Overvalued

On August 21, 2026, 908 Devices Inc (MASS) shares rose 3.3% to $10.68, marking a notable increase within its 52-week range of $5.03 to $10.70. The stock has sho

GuruFocus

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-06	-0.15	-0.22	-0.07
2026-03-03	-0.06	-0.05	0.01
2025-11-10	-0.115	-0.15	-0.035
2025-08-05	-0.16	-0.18	-0.02
2025-05-13	-0.27	-0.22	0.05
2025-03-04	-0.35	-0.32	0.03
2024-11-12	-0.29	-0.23	0.06
2024-08-06	-0.34	-0.32	0.02
2024-04-30	-0.37	-0.33	0.04
2024-03-05	-0.27	-0.23	0.04
2023-11-07	-0.3	-0.22	0.08
2023-08-08	-0.33	-0.29	0.04